ProstaPilot: A Comparative Study of Biparametric Magnetic
Resonance Imaging Versus Prostate-specific Antigen as a
Screening Test for Prostate Cancer

J 2025

ProstaPilot: A Comparative Study of Biparametric Magnetic Resonance Imaging Versus Prostate-specific Antigen as a Screening Test for Prostate Cancer

STANÍK, Michal; Michal STANDARA; David MIKLÁNEK; Kateřina HEJCMANOVÁ; Milos PACAL et al.

Základní údaje

Originální název

ProstaPilot: A Comparative Study of Biparametric Magnetic Resonance Imaging Versus Prostate-specific Antigen as a Screening Test for Prostate Cancer

Autoři

STANÍK, Michal; Michal STANDARA; David MIKLÁNEK; Kateřina HEJCMANOVÁ; Milos PACAL; Roman HRABEC; Ondřej NGO; Karel HEJDUK; Jan KRISTEK; Michal UHER; Ondřej MÁJEK a Alexandr POPRACH

Vydání

EUROPEAN UROLOGY OPEN SCIENCE, AMSTERDAM, ELSEVIER, 2025, 2666-1691

Další údaje

Jazyk

angličtina

Typ výsledku

Článek v odborném periodiku

Obor

30204 Oncology

Stát vydavatele

Nizozemské království

Utajení

není předmětem státního či obchodního tajemství

Odkazy

URL

Impakt faktor

Impact factor: 4.500 v roce 2024

Označené pro přenos do RIV

Ano

Organizační jednotka

Lékařská fakulta

Klíčová slova anglicky

Prostate cancer; Screening; Prostate-specific antigen; Magnetic resonance imaging

Štítky

14110811, 14110813, CF MAFIL, rivok

Příznaky

Mezinárodní význam, Recenzováno

Změněno: 9. 3. 2026 11:37, Mgr. Tereza Miškechová

Anotace

V originále

Background and objective: Our aim was to compare detection rates for clinically significant prostate cancer (csPC) between biparametric magnetic resonance imaging (bpMRI) and prostate-specific antigen (PSA) screening pathways in the Czech population, which has a high prevalence of opportunistic PSA testing (45% in the Methods: Between May 2022 and May 2023, 423 men aged 50-69 yr who were enrolled via volunteer-based recruitment, underwent both PSA testing and bpMRI of the prostate. Positive results were defined as PSA >= 3lg/l or a Prostate Imaging-Reporting and Data System score of 4-5. Those with positive tests were referred for further evaluation, including an MRI-targeted biopsy and a systematic 12-core biopsy. csPC was defined as any cancer of International Society of Key findings and limitations: Of the 423 men, 35 (8.3%) had at least one positive screening test. The PSA-based pathway identified 25 men (5.9%), whereas the MRI-based pathway identified 16 (3.8%) with suspicion of PC, with potential to reduce the number of biopsies required by 36%. Subsequent biopsy revealed PC in seven men (1.7%) with a positive PSA test and 14 men (3.3%) with positive MRI findings. Nonsignificant PC and csPC rates were 1.0% (n = 4) and 0.7% (n = 3) for the PSA pathway, and 1.7% and 1.7% (n = 7) for the MRI pathway, respectively. Conclusions and clinical implications: In a highly prescreened population, bpMRI may increase the csPC detection rate while reducing the number of biopsies needed in comparison to PSA-based diagnosis. However, bpMRI may also slightly increase the detection of grade group 1 cancers. Patient summary: We compared a blood test for PSA (prostate-specific antigen) and an MRI scan (magnetic resonance imaging) for detection of prostate cancer in men aged 50-69 years. We found that MRI scans may reduce the number of biopsies that need to be performed for cancer diagnosis while increasing the detection rate for cancers that are significant. (c) 2025 The Author(s). Published by Elsevier B.V. on behalf of European Association of Urology. This is an open access article under the CC BY-NC-ND license (http://creative-commons.org/licenses/by-nc-nd/4.0/).

Návaznosti

NU22-09-00539, projekt VaV

Název: ProstaPilot. Screening karcinomu prostaty pomocí magnetické rezonance se zkráceným protokolem

Investor: Ministerstvo zdravotnictví ČR, ProstaPilot. Screening karcinomu prostaty pomocí magnetické rezonance se zkráceným protokolem, Podprogram 1 - standardní

90250, velká výzkumná infrastruktura

Název: Czech-BioImaging III

Citovat

STANÍK, Michal; Michal STANDARA; David MIKLÁNEK; Kateřina HEJCMANOVÁ; Milos PACAL; Roman HRABEC; Ondřej NGO; Karel HEJDUK; Jan KRISTEK; Michal UHER; Ondřej MÁJEK a Alexandr POPRACH. ProstaPilot: A Comparative Study of Biparametric Magnetic Resonance Imaging Versus Prostate-specific Antigen as a Screening Test for Prostate Cancer. EUROPEAN UROLOGY OPEN SCIENCE. AMSTERDAM: ELSEVIER, 2025, roč. 76, June 2025, s. 7-13. ISSN 2666-1691. Dostupné z: https://doi.org/10.1016/j.euros.2025.03.016.

@article{2500960,
   author = {Staník, Michal and Standara, Michal and Miklánek, David and Hejcmanová, Kateřina and Pacal, Milos and Hrabec, Roman and Ngo, Ondřej and Hejduk, Karel and Kristek, Jan and Uher, Michal and Májek, Ondřej and Poprach, Alexandr},
   article_location = {AMSTERDAM},
   article_number = {June 2025},
   doi = {https://doi.org/10.1016/j.euros.2025.03.016},
   keywords = {Prostate cancer; Screening; Prostate-specific antigen; Magnetic resonance imaging},
   language = {eng},
   issn = {2666-1691},
   journal = {EUROPEAN UROLOGY OPEN SCIENCE},
   title = {ProstaPilot: A Comparative Study of Biparametric Magnetic Resonance Imaging Versus Prostate-specific Antigen as a Screening Test for Prostate Cancer},
   url = {https://www.sciencedirect.com/science/article/pii/S2666168325001041?via%3Dihub},
   volume = {76},
   year = {2025}
}

TY  - JOUR
ID  - 2500960
AU  - Staník, Michal - Standara, Michal - Miklánek, David - Hejcmanová, Kateřina - Pacal, Milos - Hrabec, Roman - Ngo, Ondřej - Hejduk, Karel - Kristek, Jan - Uher, Michal - Májek, Ondřej - Poprach, Alexandr
PY  - 2025
TI  - ProstaPilot: A Comparative Study of Biparametric Magnetic Resonance Imaging Versus Prostate-specific Antigen as a Screening Test for Prostate Cancer
JF  - EUROPEAN UROLOGY OPEN SCIENCE
VL  - 76
IS  - June 2025
SP  - 7-13
EP  - 7-13
PB  - ELSEVIER
SN  - 26661691
KW  - Prostate cancer
KW  - Screening
KW  - Prostate-specific antigen
KW  - Magnetic resonance imaging
UR  - https://www.sciencedirect.com/science/article/pii/S2666168325001041?via%3Dihub
N2  - Background and objective: Our aim was to compare detection rates for clinically significant prostate cancer (csPC) between biparametric magnetic resonance imaging (bpMRI) and prostate-specific antigen (PSA) screening pathways in the Czech population, which has a high prevalence of opportunistic PSA testing (45% in the Methods: Between May 2022 and May 2023, 423 men aged 50-69 yr who were enrolled via volunteer-based recruitment, underwent both PSA testing and bpMRI of the prostate. Positive results were defined as PSA >= 3lg/l or a Prostate Imaging-Reporting and Data System score of 4-5. Those with positive tests were referred for further evaluation, including an MRI-targeted biopsy and a systematic 12-core biopsy. csPC was defined as any cancer of International Society of Key findings and limitations: Of the 423 men, 35 (8.3%) had at least one positive screening test. The PSA-based pathway identified 25 men (5.9%), whereas the MRI-based pathway identified 16 (3.8%) with suspicion of PC, with potential to reduce the number of biopsies required by 36%. Subsequent biopsy revealed PC in seven men (1.7%) with a positive PSA test and 14 men (3.3%) with positive MRI findings. Nonsignificant PC and csPC rates were 1.0% (n = 4) and 0.7% (n = 3) for the PSA pathway, and 1.7% and 1.7% (n = 7) for the MRI pathway, respectively. Conclusions and clinical implications: In a highly prescreened population, bpMRI may increase the csPC detection rate while reducing the number of biopsies needed in comparison to PSA-based diagnosis. However, bpMRI may also slightly increase the detection of grade group 1 cancers. Patient summary: We compared a blood test for PSA (prostate-specific antigen) and an MRI scan (magnetic resonance imaging) for detection of prostate cancer in men aged 50-69 years. We found that MRI scans may reduce the number of biopsies that need to be performed for cancer diagnosis while increasing the detection rate for cancers that are significant. (c) 2025 The Author(s). Published by Elsevier B.V. on behalf of European Association of Urology. This is an open access article under the CC BY-NC-ND license (http://creative-commons.org/licenses/by-nc-nd/4.0/).
ER  -

STANÍK, Michal; Michal STANDARA; David MIKLÁNEK; Kateřina HEJCMANOVÁ; Milos PACAL; Roman HRABEC; Ondřej NGO; Karel HEJDUK; Jan KRISTEK; Michal UHER; Ondřej MÁJEK a Alexandr POPRACH. ProstaPilot: A Comparative Study of Biparametric Magnetic Resonance Imaging Versus Prostate-specific Antigen as a Screening Test for Prostate Cancer. \textit{EUROPEAN UROLOGY OPEN SCIENCE}. AMSTERDAM: ELSEVIER, 2025, roč.~76, June 2025, s.~7-13. ISSN~2666-1691. Dostupné z: https://doi.org/10.1016/j.euros.2025.03.016.

Přehled o publikaci